TY - JOUR
T1 - Adult growth hormone deficiency in CEE region
T2 - Heterogeneity of the patient pathway
AU - Shimon, Ilan
AU - Badiu, Corin
AU - Bossowski, Artur
AU - Doknic, Mirjana
AU - Dzivite-Krisane, Iveta
AU - Hána, Václav
AU - Kollerova, Jana
AU - Natchev, Emil
AU - Pfeifer, Marija
AU - Szũcs, Nikolette
AU - Hey-Hadavi, Juliana
AU - Gomez, Roy
N1 - Funding Information:
This study was funded by Pfizer Ltd. At the time of this study, Juliana Hey-Hadavi and Roy Gomez were full-time employees of Pfizer. The remaining authors received consulting fees from Pfizer; however, no payment was received by the authors for the development of this manuscript.
Funding Information:
This work was supported by Pfizer .
Funding Information:
Writing support for this manuscript was provided by Alex Kahney at Synergy Medical, UK and this service was funded by Pfizer. Original illustration artwork was provided by Adrian Roots and this was funded by Pfizer.
Publisher Copyright:
© 2019 The Authors
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Objectives: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. Design: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. Results: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. Conclusion: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.
AB - Objectives: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. Design: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. Results: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. Conclusion: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.
KW - Adult growth hormone deficiency (AGHD)
KW - CEE adult endocrinology advisory board
KW - Central and Eastern Europe (CEE)
KW - Growth hormone replacement therapy (GHRT)
KW - Practice guidelines
KW - Recombinant human growth hormone (rhGH)
UR - http://www.scopus.com/inward/record.url?scp=85067578056&partnerID=8YFLogxK
U2 - 10.1016/j.ghir.2019.06.001
DO - 10.1016/j.ghir.2019.06.001
M3 - Review article
C2 - 31234055
AN - SCOPUS:85067578056
SN - 1096-6374
VL - 46-47
SP - 44
EP - 49
JO - Growth Hormone and IGF Research
JF - Growth Hormone and IGF Research
ER -